CL2015002680A1 - Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos - Google Patents
Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismosInfo
- Publication number
- CL2015002680A1 CL2015002680A1 CL2015002680A CL2015002680A CL2015002680A1 CL 2015002680 A1 CL2015002680 A1 CL 2015002680A1 CL 2015002680 A CL2015002680 A CL 2015002680A CL 2015002680 A CL2015002680 A CL 2015002680A CL 2015002680 A1 CL2015002680 A1 CL 2015002680A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- ampk activator
- serotonergic agent
- agent
- disease
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- MPLLLQUZNJSVTK-UHFFFAOYSA-N 5-[3-[4-[2-(4-fluorophenyl)ethoxy]phenyl]propyl]furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CCCC(C=C1)=CC=C1OCCC1=CC=C(F)C=C1 MPLLLQUZNJSVTK-UHFFFAOYSA-N 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 title 1
- 230000000862 serotonergic effect Effects 0.000 title 1
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 abstract 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 201000002859 sleep apnea Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361793407P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2015002680A1 true CL2015002680A1 (es) | 2016-09-02 |
Family
ID=51538303
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2015002680A CL2015002680A1 (es) | 2013-03-15 | 2015-09-14 | Composición farmaceutica que comprende un activador de ampk y un agente serotoninérgico y método para usar los mismos |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20140350064A1 (enExample) |
| EP (1) | EP2983473A4 (enExample) |
| JP (1) | JP2016513734A (enExample) |
| KR (1) | KR20160005341A (enExample) |
| CN (1) | CN105636438A (enExample) |
| AR (1) | AR095631A1 (enExample) |
| AU (1) | AU2014227807B2 (enExample) |
| BR (1) | BR112015023922A2 (enExample) |
| CA (1) | CA2909633A1 (enExample) |
| CL (1) | CL2015002680A1 (enExample) |
| HK (1) | HK1222297A1 (enExample) |
| IL (1) | IL241587B (enExample) |
| MX (1) | MX2015012760A (enExample) |
| RU (1) | RU2015143438A (enExample) |
| TW (1) | TW201444552A (enExample) |
| WO (1) | WO2014144130A2 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180071269A1 (en) * | 2015-08-12 | 2018-03-15 | Tianxin Wang | Therapeutical methods, formulations and nutraceutical formulations |
| ES2567105B1 (es) * | 2014-09-19 | 2017-02-10 | Consejo Superior De Investigaciones Científicas (Csic) | Derivados de indol para la prevención y/o tratamiento de diabetes ytrastornos metabólicos relacionados |
| WO2016126662A1 (en) * | 2015-02-03 | 2016-08-11 | Kardiatonos, Inc. | Compounds for the prevention and treatment of vascular disease |
| US10463649B2 (en) | 2015-06-08 | 2019-11-05 | Texas Tech University System | Inhibitors of Mc1-1 as drugs to overcome resistance to BRAF inhibitors and MEK inhibitors |
| WO2017018752A1 (ko) * | 2015-07-29 | 2017-02-02 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| KR101663543B1 (ko) * | 2015-07-29 | 2016-10-07 | 고려대학교 산학협력단 | 부스피론 유도체 및 이를 함유하는 약학 조성물 |
| WO2017023833A1 (en) * | 2015-08-01 | 2017-02-09 | Petti Stephen J | Compositions and methods for combination pharmacological treatments to induce a prolonged, mild decrease in core body temperature |
| CN105541665A (zh) * | 2016-02-18 | 2016-05-04 | 江苏大学 | 一种抗肿瘤药物化合物及制备方法和应用 |
| KR101838625B1 (ko) * | 2016-09-20 | 2018-03-14 | 김브라이언 | 아디포넥틴 수용체에 대한 작용제 펩타이드 |
| AU2017340403B2 (en) | 2016-10-05 | 2022-03-17 | The United States as Represented by the Department of Veterans Affairs | Small molecule AMPK activators |
| CN110087641B (zh) | 2016-12-20 | 2024-03-12 | 罗曼治疗系统股份公司 | 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统 |
| PL3338768T3 (pl) | 2016-12-20 | 2020-05-18 | Lts Lohmann Therapie-Systeme Ag | Transdermalny system terapeutyczny zawierający asenapinę |
| JP2020525545A (ja) | 2017-06-26 | 2020-08-27 | エルテーエス ローマン テラピー−ジステーメ アーゲー | アセナピンおよびシリコーンアクリルハイブリッドポリマーを含有する経皮治療システム |
| CN107252425A (zh) * | 2017-07-12 | 2017-10-17 | 上海华堇生物技术有限责任公司 | 去氢延胡索素的药物用途 |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
| US11208475B1 (en) * | 2018-01-30 | 2021-12-28 | Flagship Pioneering Innovations V, Inc. | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators |
| CN108159044A (zh) * | 2018-02-26 | 2018-06-15 | 华中科技大学 | 抗坏血酸与二甲双胍的复合制剂用于制备化疗药物的应用 |
| CN118806732A (zh) | 2018-06-20 | 2024-10-22 | 罗曼治疗系统股份公司 | 含有阿塞那平的透皮治疗系统 |
| BR112020026099A2 (pt) | 2018-06-20 | 2021-03-23 | Lts Lohmann Therapie-Systeme Ag | sistema terapêutico transdérmico que contém asenapina |
| CN108997172B (zh) * | 2018-08-08 | 2020-12-15 | 中国人民解放军总医院 | 抗肿瘤化合物 |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| CN109771424B (zh) * | 2019-03-11 | 2021-03-16 | 马慧 | 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用 |
| CN109793727A (zh) * | 2019-03-13 | 2019-05-24 | 湖北科技学院 | 一种有效抗恶性肿瘤的药物组合物及其应用 |
| EP3753923A1 (en) | 2019-06-19 | 2020-12-23 | GH Research Limited | Recrystallisation of 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) in methyl tert.-butyl ether (mtbe) without adding an anti-solvent |
| AU2020345766A1 (en) | 2019-09-10 | 2022-03-03 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Methods and materials for increasing level of phosphorylated AMPK protein |
| CN110559298A (zh) * | 2019-10-28 | 2019-12-13 | 中国药科大学 | 一种天然化合物Egenine用于制备抗肾纤维化药物的用途 |
| AU2020372682A1 (en) | 2019-10-31 | 2022-06-09 | Jd Bioscience Inc. | Tricyclic compound and pharmaceutical use thereof |
| EP3868364A1 (en) | 2020-02-24 | 2021-08-25 | GH Research Limited | Aerosol comprising 5-methoxy-n,n-dimethyltryptamine |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| CN114728933B (zh) * | 2020-07-22 | 2023-06-16 | 山东绿叶制药有限公司 | 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用 |
| CN117015378A (zh) * | 2021-03-10 | 2023-11-07 | 杰那医疗公司 | 哺乳动物slc6a19功能的小分子抑制剂 |
| IL305262A (en) | 2021-03-10 | 2023-10-01 | Jnana Therapeutics Inc | Small molecule inhibitors of mammalian SLC6A19 function |
| AU2022309017A1 (en) | 2021-07-07 | 2024-01-25 | Terran Biosciences Inc. | N,n-dimethyltryptamine and related psychedlics and uses thereof |
| WO2023086962A1 (en) | 2021-11-12 | 2023-05-19 | Terran Biosciences Inc. | Psilocybin and o-acetylpsilocin, salts and solid state forms thereof |
| US20250032450A1 (en) * | 2021-11-18 | 2025-01-30 | Cybin UK Ltd. | Injectable and inhalable formulations |
| TW202440068A (zh) * | 2022-12-05 | 2024-10-16 | 美商恩維達醫療公司以恩維達生物科學公司之名營業 | 用於治療搔癢之諾卡酮（ｎｏｏｔｋａｔｏｎｅ） |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3174901A (en) * | 1963-01-31 | 1965-03-23 | Jan Marcel Didier Aron Samuel | Process for the oral treatment of diabetes |
| WO2006001278A1 (ja) * | 2004-06-28 | 2006-01-05 | Kao Corporation | Ａｍｐｋ活性化剤 |
| US20070149466A1 (en) * | 2005-07-07 | 2007-06-28 | Michael Milburn | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders |
| US7754700B2 (en) * | 2006-04-24 | 2010-07-13 | Trager Seymour F | Composition and methods for alleviating symptoms of neurotoxicity |
| SG178716A1 (en) * | 2007-01-16 | 2012-03-29 | Ipintl Llc | Novel composition for treating metabolic syndrome |
| US20120183600A1 (en) * | 2007-01-16 | 2012-07-19 | Chien-Hung Chen | Novel composition for treating metabolic syndrome and other conditions |
| WO2011112167A1 (en) * | 2009-03-13 | 2011-09-15 | Reset Therapeutics, Inc. | Compositions and methods for diabetes treatment |
| US8486922B2 (en) * | 2010-04-28 | 2013-07-16 | Chien-Hung Chen | Composition |
-
2014
- 2014-03-14 BR BR112015023922A patent/BR112015023922A2/pt not_active IP Right Cessation
- 2014-03-14 EP EP14763798.7A patent/EP2983473A4/en not_active Withdrawn
- 2014-03-14 TW TW103109748A patent/TW201444552A/zh unknown
- 2014-03-14 US US14/212,734 patent/US20140350064A1/en not_active Abandoned
- 2014-03-14 JP JP2016502780A patent/JP2016513734A/ja active Pending
- 2014-03-14 WO PCT/US2014/028413 patent/WO2014144130A2/en not_active Ceased
- 2014-03-14 CN CN201480028057.0A patent/CN105636438A/zh active Pending
- 2014-03-14 KR KR1020157029838A patent/KR20160005341A/ko not_active Withdrawn
- 2014-03-14 MX MX2015012760A patent/MX2015012760A/es unknown
- 2014-03-14 CA CA2909633A patent/CA2909633A1/en not_active Abandoned
- 2014-03-14 AU AU2014227807A patent/AU2014227807B2/en not_active Ceased
- 2014-03-14 RU RU2015143438A patent/RU2015143438A/ru unknown
- 2014-03-14 HK HK16109576.5A patent/HK1222297A1/zh unknown
- 2014-03-17 AR ARP140101258A patent/AR095631A1/es unknown
-
2015
- 2015-09-14 CL CL2015002680A patent/CL2015002680A1/es unknown
- 2015-09-16 IL IL241587A patent/IL241587B/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2983473A4 (en) | 2016-11-23 |
| JP2016513734A (ja) | 2016-05-16 |
| MX2015012760A (es) | 2016-06-17 |
| WO2014144130A3 (en) | 2015-02-05 |
| AU2014227807B2 (en) | 2018-03-08 |
| TW201444552A (zh) | 2014-12-01 |
| KR20160005341A (ko) | 2016-01-14 |
| HK1222297A1 (zh) | 2017-06-30 |
| AU2014227807A1 (en) | 2015-11-05 |
| WO2014144130A2 (en) | 2014-09-18 |
| CN105636438A (zh) | 2016-06-01 |
| AR095631A1 (es) | 2015-10-28 |
| CA2909633A1 (en) | 2014-09-18 |
| US20140350064A1 (en) | 2014-11-27 |
| BR112015023922A2 (pt) | 2017-07-18 |
| EP2983473A2 (en) | 2016-02-17 |
| IL241587B (en) | 2019-01-31 |
| RU2015143438A (ru) | 2017-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001982A1 (es) | Metodo para reducir los niveles de glucosa y tratar trastornos del metabolismo de la misma; composicion farmaceutica que comprende metformina y otro agente antidiabetico o antiobesidad. | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
| MX2013004699A (es) | Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos. | |
| CR20130377A (es) | Métodos y productos de fármaco para tratar enfermedad de alzheimer | |
| CR11723A (es) | Agente para tratar enfermedad | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| AR092925A1 (es) | Derivados de exendina-4 como agonistas duales de glp1 / glucagon | |
| ECSP13012661A (es) | Composición farmacéutica, métodos de tratamiento y usos de la misma. | |
| MX2014002668A (es) | Tratamiento de enfermedades relacionadas con subunidades alfa de canales de sonido regulados por voltaje (scnxa) con moleculas pequeñas. | |
| CO2017006308A2 (es) | Derivados de glucagón | |
| ES2570958T3 (es) | Composición para el tratamiento de la fístula | |
| CO6410278A2 (es) | Disoluciones pediátricas que continen un beta-bloqueante | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| DOP2016000253A (es) | Nuevos compuestos | |
| CL2011002650A1 (es) | Composicion que comprende n-(4-(2-furil)-5-(tetrahidropiran-4-ilcarbonil)tiazol-2-il)-2-metilpiridin-5-carboxamida y l-dopa; uso del compuesto para el tratamiento de un trastorno del movimiento secundario de la terapia con l-dopa; uso del compuesto y l-dopa y/o para el tratamiento y/o profilaxis de la enfermedad de parkinson. | |
| EA201591450A1 (ru) | Фармацевтический состав, содержащий гликозаминогликан | |
| MX376496B (es) | Agente protector para queratoconjuntiva o agente supresor para el trastorno queratoconjuntival. | |
| AR103415A1 (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 | |
| DOP2015000071A (es) | Fármaco combinado que comprende gemigliptina y metformina, y método para su preparación | |
| MX2017009325A (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| MX2016016650A (es) | Metodo para tratar el sindrome de mano-pie y sintomas asociados con el mismo. | |
| ECSP10010567A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona |